Pronostic and Predictive Value of EMT in Localized Lung Cancer
TWISTlung
EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer
1 other identifier
observational
1,000
1 country
1
Brief Summary
The goal of the present research is to identify an "EMT signature", associated with long term disease-free survival after surgery in NSCLC. This study will potentially lead to specific treatment recommendations, thanks to an integrated molecular approach including DNA, RNA and miR profiling In vitro analyses using lung cancer cell lines will subsequently be conducted to validate markers identified in tumor screenings.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 20, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2018
CompletedFirst Submitted
Initial submission to the registry
April 17, 2018
CompletedFirst Posted
Study publicly available on registry
April 26, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedSeptember 6, 2018
September 1, 2018
3.4 years
April 17, 2018
September 4, 2018
Conditions
Outcome Measures
Primary Outcomes (2)
Relapse free survival
Time to relapse after surgery
1 year
Overall survival
Time to death
5 years
Secondary Outcomes (1)
Overall survival
3 years
Study Arms (1)
NSCLC
NSCLC localized disease treated by surgery
Eligibility Criteria
All patients treated by surgery at HEGP having signed the ONCOHEGP consent are eligible to this observational study
You may qualify if:
- Patient with NSCLC stage I II IIIA IIIB, treated by surgery at Georges Pompidou Hospital (HEGP) Informed consent ONCOHEGP signed
You may not qualify if:
- Informed consent ONCOHEGP not signed
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- European Georges Pompidou Hospitallead
- APHPcollaborator
Study Sites (1)
Aphp Hegp
Paris, 75015, France
Related Publications (1)
Garinet S, Didelot A, Marisa L, Beinse G, Sroussi M, Le Pimpec-Barthes F, Fabre E, Gibault L, Laurent-Puig P, Mouillet-Richard S, Legras A, Blons H. A novel Chr1-miR-200 driven whole transcriptome signature shapes tumor immune microenvironment and predicts relapse in early-stage lung adenocarcinoma. J Transl Med. 2023 May 15;21(1):324. doi: 10.1186/s12967-023-04086-7.
PMID: 37189151DERIVED
Biospecimen
Tumor samples analyzed for somatic mutations using NGS
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Francoise Lepimpec Barthes, MD PhD
APHP
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 17, 2018
First Posted
April 26, 2018
Study Start
October 20, 2014
Primary Completion
March 31, 2018
Study Completion
December 31, 2025
Last Updated
September 6, 2018
Record last verified: 2018-09
Data Sharing
- IPD Sharing
- Will not share